Kelvitel-H Tablet contains a combination of Telmisartan 40 mg and Hydrochlorothiazide 12.5 mg, formulated for the management of hypertension. Telmisartan is an angiotensin II receptor antagonist that selectively blocks the binding of angiotensin II to the AT1 receptor, thereby inhibiting vasoconstriction and aldosterone secretion, which results in vasodilation and reduction of blood pressure. Hydrochlorothiazide is a thiazide diuretic that promotes the excretion of sodium and water by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, leading to decreased plasma volume and reduced peripheral vascular resistance. The combination of these two agents provides complementary mechanisms for effective blood pressure control, improving cardiovascular outcomes and reducing the risk of stroke, myocardial infarction, and renal complications associated with hypertension. Kelvitel-H is indicated for patients whose blood pressure is not adequately controlled with monotherapy. It should be used under medical supervision with periodic monitoring of electrolytes, renal function, and blood pressure. Caution is advised in patients with renal or hepatic impairment, electrolyte imbalances, or hypersensitivity to sulfonamides. Adverse effects may include dizziness, hypotension, electrolyte disturbances, and gastrointestinal discomfort. This medication should be taken as prescribed to achieve optimal therapeutic benefits.